1. Immunology/Inflammation
  2. PD-1/PD-L1

PD-1/PD-L1

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

PD-1/PD-L1 Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-19745
    BMS-202 Inhibitor 99.63%
    BMS-202 is an inhibitor of the PD-1/PD-L1 protein/protein interaction, mainly used for cancer treatment.
  • HY-19991
    PD1-PDL1 inhibitor 1 Inhibitor 99.85%
    PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-L1 protein/protein interaction, is an immunomodulator.
  • HY-101093
    PD-1-IN-1 Inhibitor 98.48%
    PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.